{
  "meta": {
    "title": "Vasculitis",
    "url": "https://brainandscalpel.vercel.app/vasculitis-1c828cbe.html",
    "scrapedAt": "2025-11-29T18:25:18.274Z"
  },
  "questions": [
    {
      "id": 38943,
      "choices": [
        {
          "id": 155511,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obtaining a biopsy sample from the most tender area of the artery </span></span></span></p>"
        },
        {
          "id": 155512,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Using a large bore needle for biopsy </span></span></span></p>"
        },
        {
          "id": 155513,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obtaining a biopsy segment of at least 3-5 cm in length </span></span></span></p>"
        },
        {
          "id": 155514,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Performing the biopsy under general anesthesia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a temporal artery biopsy for suspected giant cell arteritis, which of the following factors is MOST important for improving diagnostic yield?</span></span></p>",
      "unique_key": "Q5995110",
      "question_audio": null,
      "question_video": null,
      "map_id": 24081,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Obtaining a biopsy segment of at least 3-5 cm in length</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Due to the segmental (patchy) nature of vascular inflammation in giant cell arteritis, obtaining a longer segment (3-5 cm) of the temporal artery is crucial to increase the chances of finding the diagnostic histopathological changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Obtaining a biopsy sample from the most tender area of the artery:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While tenderness might indicate inflammation,&nbsp;a longer segment is more important for sampling.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Using a large bore needle for biopsy:&nbsp;</span></strong><span style=\"font-size:12.0pt\">The needle size is less relevant than the length of the biopsy specimen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Performing the biopsy under general anesthesia:&nbsp;</span></strong><span style=\"font-size:12.0pt\">General anesthesia is not typically required.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adequate biopsy length is essential for accurate diagnosis of GCA. While other factors like tenderness or imaging findings can guide the biopsy site, the length of the specimen is the most critical determinant of diagnostic yield.</span></span></span></p>",
      "correct_choice_id": 155513,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 38944,
      "choices": [
        {
          "id": 155515,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue prednisone and observe for symptom resolution</span></span></span></p>"
        },
        {
          "id": 155516,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Order a temporal artery ultrasound</span></span></span></p>"
        },
        {
          "id": 155517,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Perform a temporal artery biopsy</span></span></span></p>"
        },
        {
          "id": 155518,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase the dose of prednisone</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old woman presents with a 2-week history of headaches, jaw claudication, and scalp tenderness. She has been taking low-dose prednisone for polymyalgia rheumatica (PMR) for the past 5 days. Which of the following is the most appropriate next step?</span></span></p>",
      "unique_key": "Q1681160",
      "question_audio": null,
      "question_video": null,
      "map_id": 24082,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Perform a temporal artery biopsy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While glucocorticoids can improve symptoms, they may not completely suppress vascular inflammation. Biopsy should be performed promptly, even if the patient is already on glucocorticoids, as histologic findings may still be present.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Discontinue prednisone and observe for symptom resolution:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While low-dose prednisone may be used to manage polymyalgia rheumatica (PMR),&nbsp;it&#39;s not sufficient to treat giant cell arteritis (GCA).&nbsp;Discontinuing it without a definitive diagnosis could lead to worsening symptoms and potentially irreversible vision loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Order a temporal artery ultrasound:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While ultrasound can be a helpful tool in the assessment of GCA,&nbsp;it is not as definitive as a biopsy.&nbsp;A negative ultrasound doesn&#39;t rule out GCA,&nbsp;and a positive result still requires biopsy confirmation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Increase the dose of prednisone:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Increasing the dose of prednisone without a biopsy-confirmed diagnosis of GCA is not recommended.&nbsp;Higher doses of prednisone carry a significant risk of side effects,&nbsp;and it&#39;s important to establish the diagnosis first to determine the appropriate treatment course. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early diagnosis and treatment of GCA are crucial to prevent complications like vision loss. Even if a patient is already on glucocorticoids, a biopsy should not be delayed, as it is the gold standard for confirming the diagnosis.</span></span></span></p>",
      "correct_choice_id": 155517,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 38945,
      "choices": [
        {
          "id": 155519,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continue with oral prednisone 40 mg daily </span></span></span></p>"
        },
        {
          "id": 155520,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase the dose of oral prednisone to 60 mg daily </span></span></span></p>"
        },
        {
          "id": 155521,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer intravenous methylprednisolone 1000 mg daily for 3 days </span></span></span></p>"
        },
        {
          "id": 155522,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Refer urgently to ophthalmology for assessment</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old woman with newly diagnosed temporal arteritis complains of blurred vision in one eye. Which of the following is the most appropriate immediate intervention?</span></span></p>",
      "unique_key": "Q1638291",
      "question_audio": null,
      "question_video": null,
      "map_id": 24083,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Administer intravenous methylprednisolone 1000 mg daily for 3 days</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous high-dose methylprednisolone is the recommended initial treatment for visual manifestations in temporal arteritis to prevent further vision loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Continue with oral prednisone 40 mg daily:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Oral prednisone is the standard treatment for temporal arteritis,&nbsp;but higher doses or IV steroids are needed for ocular involvement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Refer urgently to ophthalmology for assessment:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Ophthalmology referral is essential,&nbsp;but not the immediate first step</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prompt recognition and treatment of visual symptoms in temporal arteritis are critical to preserve vision. High-dose intravenous glucocorticoids are the mainstay of initial therapy for ocular involvement.</span></span></span></p>",
      "correct_choice_id": 155521,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 38946,
      "choices": [
        {
          "id": 155523,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Methotrexate </span></span></span></p>"
        },
        {
          "id": 155524,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Rituximab </span></span></span></p>"
        },
        {
          "id": 155525,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Tocilizumab </span></span></span></p>"
        },
        {
          "id": 155526,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Infliximab</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old woman presents with new-onset headache, jaw claudication, and scalp tenderness. Her erythrocyte sedimentation rate (ESR) is elevated. Which of the following medications is FDA approved for the treatment of giant cell arteritis (GCA)?</span></span></p>",
      "unique_key": "Q5580213",
      "question_audio": null,
      "question_video": null,
      "map_id": 24084,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Tocilizumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tocilizumab, an IL-6 receptor antagonist, is specifically approved by the FDA for treating GCA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Methotrexate&nbsp;</span></strong><span style=\"font-size:12.0pt\">and<strong> Option B. Rituximab</strong> are not FDA-approved for GCA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Infliximab</span></strong><span style=\"font-size:12.0pt\"> is a TNF inhibitor and is not used in GCA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While glucocorticoids remain the first-line treatment for GCA, tocilizumab is an important alternative for patients who cannot tolerate glucocorticoids or who experience relapses despite glucocorticoid therapy. It is essential to be aware of the available treatment options for GCA to provide optimal care for patients.</span></span></span></p>",
      "correct_choice_id": 155525,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 38947,
      "choices": [
        {
          "id": 155527,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chest X-ray </span></span></span></p>"
        },
        {
          "id": 155528,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doppler ultrasound of the carotid arteries </span></span></span></p>"
        },
        {
          "id": 155529,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Contrast-enhanced CT angiography </span></span></span></p>"
        },
        {
          "id": 155530,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Magnetic resonance angiography (MRA)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman presents with fatigue, weight loss, and claudication in her arms and legs. Physical exam reveals diminished pulses in the upper extremities and a carotid bruit. Which of the following imaging modalities is the GOLD STANDARD for confirming the diagnosis of Takayasu arteritis?</span></span></p>",
      "unique_key": "Q2031370",
      "question_audio": null,
      "question_video": null,
      "map_id": 24085,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Contrast-enhanced CT angiography</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While all options can be helpful in the evaluation of Takayasu arteritis (TAK), contrast-enhanced CT angiography is considered the gold standard for visualizing the characteristic arterial wall thickening, stenosis, and aneurysms in large vessels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chest X-ray:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Chest X-ray is not sensitive enough to detect early vascular changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Doppler ultrasound of the carotid arteries:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Doppler ultrasound can assess blood flow but is limited in visualizing the arterial wall in detail.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Magnetic resonance angiography (MRA):&nbsp;</span></strong><span style=\"font-size:12.0pt\">MRA is a good alternative to CT angiography,&nbsp;but CT is often more readily available.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the gold standard imaging modality for TAK is essential for timely diagnosis and appropriate management. While other imaging modalities can provide supportive evidence, CT angiography remains the most definitive diagnostic tool.</span></span></span></p>",
      "correct_choice_id": 155529,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 38948,
      "choices": [
        {
          "id": 155531,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Giant cell arteritis </span></span></span></p>"
        },
        {
          "id": 155532,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polyarteritis nodosa </span></span></span></p>"
        },
        {
          "id": 155533,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kawasaki disease </span></span></span></p>"
        },
        {
          "id": 155534,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Takayasu arteritis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old Asian woman presents with fatigue, weight loss, and arm claudication. Physical exam reveals a blood pressure discrepancy between arms and diminished brachial pulses. Which of the following diagnoses is most likely?</span></span></p>",
      "unique_key": "Q2881400",
      "question_audio": null,
      "question_video": null,
      "map_id": 24086,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Takayasu arteritis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s young age, Asian ethnicity, constitutional symptoms, and vascular findings (pulse discrepancy, claudication) are classic for Takayasu arteritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Giant cell arteritis:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Typically affects older individuals and involves cranial arteries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Polyarteritis nodosa:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Affects medium-sized arteries and presents with multisystem involvement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Kawasaki disease: </span></strong><span style=\"font-size:12.0pt\">Kawasaki disease is a childhood vasculitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Takayasu arteritis is a large vessel vasculitis that predominantly affects young women, particularly those of Asian descent. It is important to consider this diagnosis in patients presenting with characteristic clinical features and to initiate prompt evaluation and treatment to prevent complications.</span></span></span></p>",
      "correct_choice_id": 155534,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 38949,
      "choices": [
        {
          "id": 155535,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antineutrophil cytoplasmic antibody (ANCA) testing </span></span></span></p>"
        },
        {
          "id": 155536,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Biopsy of a skin nodule </span></span></span></p>"
        },
        {
          "id": 155537,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Abdominal ultrasound </span></span></span></p>"
        },
        {
          "id": 155538,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Electromyography (EMG)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man with a history of hepatitis B presents with fever, weight loss, and abdominal pain. He also complains of new-onset muscle weakness and skin nodules. Which of the following diagnostic tests would have the HIGHEST diagnostic yield for polyarteritis nodosa (PAN)?</span></span></p>",
      "unique_key": "Q3448102",
      "question_audio": null,
      "question_video": null,
      "map_id": 24087,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Biopsy of a skin nodule</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Biopsy of symptomatic tissues like skin nodules in PAN offers the highest diagnostic yield, revealing necrotizing vasculitis with fibrinoid necrosis and inflammatory cell infiltrates.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong> <strong><span style=\"font-size:12.0pt\">Antineutrophil cytoplasmic antibody (ANCA) testing:&nbsp;</span></strong><span style=\"font-size:12.0pt\">ANCA is usually negative in PAN.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Abdominal ultrasound:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Ultrasound might show organ ischemia,&nbsp;but not the underlying vasculitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Electromyography (EMG):&nbsp;</span></strong><span style=\"font-size:12.0pt\">EMG can assess muscle involvement but is not diagnostic</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When suspecting PAN, a tissue biopsy of an affected organ (such as skin, nerve, or muscle) is the most reliable diagnostic test. While other tests can provide supportive evidence, biopsy provides definitive proof of vasculitis</span></span></span></p>",
      "correct_choice_id": 155536,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 38950,
      "choices": [
        {
          "id": 155539,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nephrotic syndrome </span></span></span></p>"
        },
        {
          "id": 155540,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rapidly progressive glomerulonephritis (RPGN) </span></span></span></p>"
        },
        {
          "id": 155541,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Renal failure and hypertension </span></span></span></p>"
        },
        {
          "id": 155542,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nephrolithiasis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old man with a recent diagnosis of polyarteritis nodosa (PAN) is most likely to present with which of the following renal manifestations?</span></span></p>",
      "unique_key": "Q1772839",
      "question_audio": null,
      "question_video": null,
      "map_id": 24088,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Renal failure and hypertension</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Renal involvement occurs in 60% of PAN cases and typically manifests as renal failure and hypertension due to the vasculitic involvement of the renal arteries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Nephrotic syndrome</span></strong><span style=\"font-size:12.0pt\">: This is characterized by heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia. It&#39;s not the typical presentation of renal involvement in PAN.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Rapidly progressive glomerulonephritis (RPGN):</span></strong><span style=\"font-size:12.0pt\">&nbsp;While RPGN can cause renal failure,&nbsp;it&#39;s less common in PAN and usually associated with other vasculitides like microscopic polyangiitis or granulomatosis with polyangiitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Nephrolithiasis (Kidney Stones):</span></strong><span style=\"font-size:12.0pt\">&nbsp;Kidney stones are not directly related to the vasculitic process of PAN</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PAN commonly affects the kidneys, leading to hypertension and renal failure. Recognizing this association is crucial for early diagnosis and appropriate management to prevent irreversible kidney damage.</span></span></span></p>",
      "correct_choice_id": 155541,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19696,
      "choices": [
        {
          "id": 78745,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Scarlet fever&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span></p>"
        },
        {
          "id": 78746,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Measles </span></span></span></p>"
        },
        {
          "id": 78747,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kawasaki disease </span></span></span></p>"
        },
        {
          "id": 78748,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Infectious mononucleosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 3-year-old child presents with a 5-day history of high fever, bilateral conjunctivitis, erythema of the oral mucosa and lips, and cervical lymphadenopathy. The child&rsquo;s tongue is shown below. Which of the following diagnoses is most likely?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/29/screenshot-2024-07-29-174133.png\" style=\"height:330px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q5131197",
      "question_audio": null,
      "question_video": null,
      "map_id": 19508,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Kawasaki disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of fever, conjunctivitis, oral mucosa changes, lymphadenopathy, and rash (erythema of the palms) is classic for Kawasaki disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Scarlet fever</span></strong><span style=\"font-size:12.0pt\"> typically presents with a sandpaper-like rash and sore throat.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Measles</span></strong><span style=\"font-size:12.0pt\"> has a characteristic maculopapular rash and Koplik spots in the mouth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Infectious mononucleosis</span></strong><span style=\"font-size:12.0pt\"> is associated with fatigue,&nbsp;lymphadenopathy,&nbsp;and atypical lymphocytes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the characteristic clinical features of Kawasaki disease is crucial for timely diagnosis and treatment to prevent complications, such as coronary artery aneurysms.</span></span></span></p>",
      "correct_choice_id": 78747,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19698,
      "choices": [
        {
          "id": 78753,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Granulomatous inflammation with giant cells </span></span></span></p>"
        },
        {
          "id": 78754,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Transmural inflammation with fibrinoid necrosis </span></span></span></p>"
        },
        {
          "id": 78755,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intimal proliferation and infiltration of mononuclear cells </span></span></span></p>"
        },
        {
          "id": 78756,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Medial calcification and fibrosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-year-old child with Kawasaki disease is found to have coronary artery aneurysms on echocardiogram. Which of the following histopathological findings would most likely be present in the affected coronary arteries?</span></span></p>",
      "unique_key": "Q3540903",
      "question_audio": null,
      "question_video": null,
      "map_id": 19509,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Intimal proliferation and infiltration of mononuclear cells</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The characteristic histopathology of Kawasaki disease in coronary arteries is intimal proliferation (thickening of the innermost layer) with infiltration of mononuclear cells (lymphocytes and macrophages).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Granulomatous inflammation with giant cells:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Granulomatous inflammation is seen in conditions like giant cell arteritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Transmural inflammation with fibrinoid necrosis:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Transmural inflammation with fibrinoid necrosis is seen in polyarteritis nodosa.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Medial calcification and fibrosis:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Medial calcification and fibrosis&nbsp;are more typical of atherosclerosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding the pathological changes in coronary arteries caused by Kawasaki disease is important for recognizing the potential for long-term cardiovascular complications.</span></span></span></p>",
      "correct_choice_id": 78755,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19700,
      "choices": [
        {
          "id": 78761,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery stenting </span></span></span></p>"
        },
        {
          "id": 78762,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pericardiectomy </span></span></span></p>"
        },
        {
          "id": 78763,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thromboendarterectomy and aneurysmal reconstruction </span></span></span></p>"
        },
        {
          "id": 78764,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac transplantation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 7-year-old boy with a history of Kawasaki disease presents with chest pain and signs of myocardial ischemia. Echocardiogram reveals giant coronary artery aneurysms with evidence of thrombosis. Which of the following surgical interventions is MOST likely to be considered for this patient?</span></span></p>",
      "unique_key": "Q2523180",
      "question_audio": null,
      "question_video": null,
      "map_id": 19510,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Thromboendarterectomy and aneurysmal reconstruction</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a child with Kawasaki disease and giant coronary aneurysms with thrombosis, thromboendarterectomy (removal of the clot) followed by aneurysmal reconstruction aims to restore coronary blood flow and prevent myocardial ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Coronary artery stenting:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Stenting is less suitable for giant aneurysms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pericardiectomy:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Pericardiectomy is the removal of the pericardium and is not relevant to coronary artery disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cardiac transplantation:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Cardiac transplantation is a last resort for severe,&nbsp;refractory cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Timely surgical intervention is crucial for managing giant coronary artery aneurysms in Kawasaki disease to prevent life-threatening complications like myocardial infarction and sudden cardiac death.</span></span></span></p>",
      "correct_choice_id": 78763,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19701,
      "choices": [
        {
          "id": 78765,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10 mg/kg/day </span></span></span></p>"
        },
        {
          "id": 78766,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">20 mg/kg/day </span></span></span></p>"
        },
        {
          "id": 78767,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50 mg/kg/day </span></span></span></p>"
        },
        {
          "id": 78768,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">80-100 mg/kg/day</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 3-year-old boy presents with fever, rash, conjunctival injection, and swollen glands, raising suspicion for Kawasaki disease. What is the most likely initial dose of aspirin that would be prescribed by the doctor?</span></span></p>",
      "unique_key": "Q1144498",
      "question_audio": null,
      "question_video": null,
      "map_id": 19511,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) 80-100 mg/kg/day</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-dose aspirin (80-100 mg/kg/day) is the standard initial treatment for Kawasaki disease due to its anti-inflammatory and antipyretic effects. This high dose is necessary to manage the acute phase of the illness and reduce the risk of coronary artery complications. Once the fever subsides, the aspirin dose is typically lowered to 3-5 mg/kg/day for its antiplatelet effect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 10 mg/kg/day:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a low dose of aspirin and would not be sufficient for the anti-inflammatory effect needed in acute Kawasaki disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 20 mg/kg/day:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This dose is also too low for the initial treatment of Kawasaki disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 50 mg/kg/day:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This dose may be appropriate for some children,&nbsp;but the standard initial dose is generally higher.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-dose aspirin (80-100 mg/kg/day) is the standard initial treatment for Kawasaki disease due to its anti-inflammatory and antipyretic (fever-reducing) effects. This higher dose is crucial during the acute phase of the illness to control inflammation and potentially reduce the risk of coronary artery complications. Once the fever subsides, the aspirin dose is typically tapered down to a lower dose (3-5 mg/kg/day) for its antiplatelet effect.</span></span></span></p>",
      "correct_choice_id": 78768,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19703,
      "choices": [
        {
          "id": 78773,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive rheumatoid factor </span></span></span></p>"
        },
        {
          "id": 78774,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated antinuclear antibody (ANA) titer </span></span></span></p>"
        },
        {
          "id": 78775,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA) </span></span></span></p>"
        },
        {
          "id": 78776,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eosinophilia on complete blood count (CBC)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with a history of recurrent sinusitis and chronic cough now presents with bloody nasal discharge and a new saddle nose deformity. Which additional finding would MOST strongly support a diagnosis of granulomatosis with polyangiitis (GPA)?</span></span></p>",
      "unique_key": "Q9625770",
      "question_audio": null,
      "question_video": null,
      "map_id": 19512,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Positive cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">c-ANCA (especially anti-PR3 antibodies) are highly specific for GPA and their presence strongly supports the diagnosis in a patient with characteristic clinical features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Positive rheumatoid factor&nbsp;</span></strong><span style=\"font-size:12.0pt\">and<strong> Option B. Elevated antinuclear antibody (ANA) titer are</strong> not specific for GPA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Eosinophilia on complete blood count (CBC):&nbsp;</span></strong><span style=\"font-size:12.0pt\">Eosinophilia is more characteristic of eosinophilic granulomatosis with polyangiitis (EGPA).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the significance of c-ANCA positivity in the context of suspected GPA is crucial for early diagnosis and prompt initiation of treatment to prevent irreversible organ damage.</span></span></span></p>",
      "correct_choice_id": 78775,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19705,
      "choices": [
        {
          "id": 78781,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is the most common cause of mortality in untreated GPA</span></span></span></p>"
        },
        {
          "id": 78782,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It typically presents with rapidly progressive renal failure</span></span></span></p>"
        },
        {
          "id": 78783,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is often associated with pulmonary hemorrhage</span></span></span></p>"
        },
        {
          "id": 78784,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It can be effectively treated with immunosuppressive therapy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about renal involvement in GPA is FALSE?</span></span></p>",
      "unique_key": "Q7482564",
      "question_audio": null,
      "question_video": null,
      "map_id": 19513,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) It is often associated with pulmonary hemorrhage.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While pulmonary hemorrhage can occur in GPA, it is less commonly associated with renal involvement compared to other manifestations like upper airway disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The other statements are true regarding renal involvement in GPA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding the patterns of organ involvement in GPA is important for accurate diagnosis and management. While renal involvement is a serious complication, it is not typically associated with pulmonary hemorrhage.</span></span></span></p>",
      "correct_choice_id": 78783,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19707,
      "choices": [
        {
          "id": 78789,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral prednisone 1 mg/kg/day </span></span></span></p>"
        },
        {
          "id": 78790,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate 25 mg/week </span></span></span></p>"
        },
        {
          "id": 78791,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab 375 mg/m2 weekly for 4 weeks </span></span></span></p>"
        },
        {
          "id": 78792,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous methylprednisolone 1000 mg daily for 3 days</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with GPA presents with rapidly progressive glomerulonephritis and diffuse alveolar hemorrhage. Which of the following is the most appropriate initial treatment?</span></span></p>",
      "unique_key": "Q6012620",
      "question_audio": null,
      "question_video": null,
      "map_id": 19514,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Intravenous methylprednisolone 1000 mg daily for 3 days</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-dose intravenous methylprednisolone is the initial treatment of choice for life-threatening manifestations of GPA like rapidly progressive glomerulonephritis and alveolar hemorrhage. It provides rapid and potent anti-inflammatory effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Oral prednisone 1 mg/kg/day:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Oral prednisone is too slow and less potent for this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Methotrexate 25 mg/week:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Methotrexate is a DMARD and not appropriate for acute life-threatening disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Rituximab 375 mg/m2 weekly for 4 weeks:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Rituximab is an option,&nbsp;but high-dose glucocorticoids are typically used first.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the need for rapid intervention with high-dose glucocorticoids in patients with life-threatening manifestations of GPA is essential for optimal management and improved outcomes. Early diagnosis and aggressive treatment can significantly reduce morbidity and mortality associated with this disease.</span></span></span></p>",
      "correct_choice_id": 78792,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19708,
      "choices": [
        {
          "id": 78793,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leukocytoclastic vasculitis</span></span></span></p>"
        },
        {
          "id": 78794,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fibrinoid necrosis without granulomas</span></span></span></p>"
        },
        {
          "id": 78795,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Granulomas with eosinophilic infiltration</span></span></span></p>"
        },
        {
          "id": 78796,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphocytic vasculitis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with asthma, eosinophilia, and a skin biopsy revealing a necrotizing vasculitis with extravascular granulomas. Which of the following histopathological findings is most characteristic of EGPA?</span></span></p>",
      "unique_key": "Q2435720",
      "question_audio": null,
      "question_video": null,
      "map_id": 19515,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Granulomas with eosinophilic infiltration</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of granulomas with a prominent eosinophilic infiltrate is a hallmark of EGPA. While the other options may be seen in vasculitis, they are not specific to EGPA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Leukocytoclastic vasculitis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This type of vasculitis is characterized by the fragmentation of neutrophils (leukocytoclasis) in small blood vessel walls.&nbsp;While it can be seen in EGPA,&nbsp;it is not specific and can occur in other vasculitides as well.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Fibrinoid necrosis without granulomas:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Fibrinoid necrosis,&nbsp;a type of tissue damage,&nbsp;is often present in various vasculitides,&nbsp;including EGPA.&nbsp;However,&nbsp;the absence of granulomas makes this finding less specific for EGPA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lymphocytic vasculitis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This refers to vasculitis with predominantly lymphocytic infiltration.&nbsp;While lymphocytes may be present in EGPA lesions,&nbsp;the predominance of eosinophils and the presence of granulomas are more characteristic features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the unique histological pattern of granulomas with eosinophils is crucial for diagnosing EGPA. This finding, combined with clinical and serological evidence, can confirm the diagnosis and guide treatment decisions.</span></span></span></p>",
      "correct_choice_id": 78795,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19709,
      "choices": [
        {
          "id": 78797,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">25% </span></span></span></p>"
        },
        {
          "id": 78798,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">55% </span></span></span></p>"
        },
        {
          "id": 78799,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">63% </span></span></span></p>"
        },
        {
          "id": 78800,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">72%</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Eosinophilic granulomatosis with polyangiitis (EGPA) can affect multiple organ systems. What is the approximate percentage of EGPA patients who experience mononeuritis multiplex (MM), the second most common manifestation of this disease?</span></span></p>",
      "unique_key": "Q1891763",
      "question_audio": null,
      "question_video": null,
      "map_id": 19516,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) 72%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mononeuritis multiplex (MM) is a characteristic neurological manifestation of EGPA, occurring in up to 72% of patients. It is the second most common manifestation after pulmonary involvement. MM involves damage to two or more separate nerve areas, resulting in asymmetric sensory and motor deficits.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding the prevalence of MM in EGPA is essential for recognizing potential neurological complications and initiating appropriate management. Early diagnosis and treatment can prevent irreversible nerve damage.</span></span></span></p>",
      "correct_choice_id": 78800,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19710,
      "choices": [
        {
          "id": 78801,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral prednisone alone </span></span></span></p>"
        },
        {
          "id": 78802,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate and prednisone </span></span></span></p>"
        },
        {
          "id": 78803,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cyclophosphamide and prednisone </span></span></span></p>"
        },
        {
          "id": 78804,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab and prednisone</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man with a history of asthma and eosinophilia presents with new-onset shortness of breath, chest pain, and fatigue. He has recently been diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA). An echocardiogram reveals significant LV dysfunction and evidence of myocarditis. Which of the following treatment regimens is most appropriate for this patient?</span></span></p>",
      "unique_key": "Q1591773",
      "question_audio": null,
      "question_video": null,
      "map_id": 19517,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Cyclophosphamide and prednisone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with severe or life-threatening EGPA, particularly those with cardiac involvement, require aggressive treatment with a combination of cyclophosphamide and high-dose prednisone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Oral prednisone alone: </span></strong><span style=\"font-size:12.0pt\">Oral prednisone alone is insufficient for severe disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Methotrexate and prednisone: </span></strong><span style=\"font-size:12.0pt\">Methotrexate is less potent than cyclophosphamide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Rituximab and prednisone:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Rituximab is an option for refractory disease or in those who cannot tolerate cyclophosphamide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Severe EGPA, especially with cardiac involvement, requires aggressive treatment to achieve remission and prevent complications. Cyclophosphamide and prednisone are the mainstay of initial therapy, but other immunosuppressive agents like rituximab may be considered in refractory cases or when cyclophosphamide is contraindicated.</span></span></span></p>",
      "correct_choice_id": 78803,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19711,
      "choices": [
        {
          "id": 78805,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-glomerular basement membrane (GBM) antibodies </span></span></span></p>"
        },
        {
          "id": 78806,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antinuclear antibodies (ANA) </span></span></span></p>"
        },
        {
          "id": 78807,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) </span></span></span></p>"
        },
        {
          "id": 78808,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-proteinase 3 (PR3) antibodies</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old woman presents with a purpuric rash, hematuria, and hemoptysis. Renal biopsy reveals a pauci-immune necrotizing crescentic glomerulonephritis. Which of the following serological markers is MOST likely to be positive in this patient?</span></span></p>",
      "unique_key": "Q7838818",
      "question_audio": null,
      "question_video": null,
      "map_id": 19518,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">p-ANCA:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Microscopic polyangiitis (MPA) is strongly associated with positive p-ANCA,&nbsp;typically targeting myeloperoxidase (MPO).&nbsp;This finding,&nbsp;along with the pauci-immune crescentic glomerulonephritis on biopsy and the clinical presentation,&nbsp;is highly suggestive of MPA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Anti- Glomerular Basement Membrane (GBM) antibodies:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">These are characteristic of Goodpasture syndrome,&nbsp;which usually presents with pulmonary hemorrhage and rapidly progressive glomerulonephritis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Antinuclear antibodies (ANA):</span></strong><span style=\"font-size:12.0pt\">&nbsp;While ANA can be positive in some vasculitides,&nbsp;it is not specific for MPA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Anti-</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Proteinase 3(PR3) antibodies:&nbsp;</strong>These are cytoplasmic ANCA (c-ANCA) and are more specific for granulomatosis with polyangiitis (GPA).</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microscopic polyangiitis (MPA) is a small vessel vasculitis characterized by kidney inflammation, lung involvement, skin involvement, and possible involvement of other organs.Testing p-ANCA, especially against myeloperoxidase (MPO), is a key diagnostic marker for MPA, found in about 70% of patients.</span></span></span></p>",
      "correct_choice_id": 78807,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19712,
      "choices": [
        {
          "id": 78809,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antinuclear antibody (ANA) testing </span></span></span></p>"
        },
        {
          "id": 78810,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum IgA levels</span></span></span></p>"
        },
        {
          "id": 78811,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Skin biopsy with immunofluorescence </span></span></span></p>"
        },
        {
          "id": 78812,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Abdominal ultrasound</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-year-old child presents with a purpuric rash on the lower extremities and buttocks, abdominal pain, and joint swelling. Which of the following diagnostic approaches would be MOST helpful in confirming a diagnosis of IgA vasculitis (Henoch-Sch&ouml;nlein purpura)?</span></span></p>",
      "unique_key": "Q3674417",
      "question_audio": null,
      "question_video": null,
      "map_id": 19519,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Skin biopsy with immunofluorescence</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Skin biopsy with immunofluorescence:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is the most definitive diagnostic test for IgA vasculitis.&nbsp;It reveals leukocytoclastic vasculitis (inflammation of small blood vessels) with predominant IgA deposition in vessel walls,&nbsp;along with complement C3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Antinuclear antibody (ANA) testing:&nbsp;</strong>ANA is typically negative in IgA vasculitis,&nbsp;and a positive result would suggest a different autoimmune condition.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Serum IgA levels:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While IgA levels may be elevated in IgA vasculitis,&nbsp;they are not specific for the disease and can be elevated in other conditions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Abdominal ultrasound:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Abdominal ultrasound can help assess for gastrointestinal complications (e.g.,&nbsp;intussusception) in IgA vasculitis,&nbsp;but it does not confirm the diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While other tests may provide supportive evidence, a skin biopsy with immunofluorescence remains the gold standard for definitive diagnosis.</span></span></span></p>",
      "correct_choice_id": 78811,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19713,
      "choices": [
        {
          "id": 78813,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type I cryoglobulinemia </span></span></span></p>"
        },
        {
          "id": 78814,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type II cryoglobulinemia</span></span></span></p>"
        },
        {
          "id": 78815,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type III cryoglobulinemia </span></span></span></p>"
        },
        {
          "id": 78816,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Type IV cryoglobulinemia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old man with a history of Hepatitis C presents with fatigue, arthralgia, palpable purpura on the lower extremities, and peripheral neuropathy. Laboratory tests reveal elevated rheumatoid factor and low complement levels. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q1412402",
      "question_audio": null,
      "question_video": null,
      "map_id": 19520,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Type II cryoglobulinemia </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hepatitis C is strongly linked to type II cryoglobulinemia, which is characterized by a mixture of monoclonal IgM and polyclonal IgG.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Type I cryoglobulinemia</span></strong><span style=\"font-size:12.0pt\">: Type I is associated with lymphoproliferative disorders.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Type III cryoglobulinemia:</span></strong><span style=\"font-size:12.0pt\"> Type III is associated with autoimmune diseases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Type IV cryoglobulinemia</span></strong><span style=\"font-size:12.0pt\">: There is no type IV cryoglobulinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the association between Hepatitis C and type II cryoglobulinemia is crucial for accurate diagnosis and management of cryoglobulinemic vasculitis.</span></span></span></p>",
      "correct_choice_id": 78814,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19714,
      "choices": [
        {
          "id": 78817,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No improvement in vasculitis activity </span></span></span></p>"
        },
        {
          "id": 78818,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Worsening of vasculitis </span></span></span></p>"
        },
        {
          "id": 78819,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Complete resolution of vasculitis </span></span></span></p>"
        },
        {
          "id": 78820,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Partial improvement with decreased cryoglobulin levels</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with hepatitis C-associated cryoglobulinemic vasculitis has achieved sustained virologic response (SVR) after antiviral therapy. Which of the following is the most likely outcome regarding their vasculitis?</span></span></p>",
      "unique_key": "Q4466554",
      "question_audio": null,
      "question_video": null,
      "map_id": 19521,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Partial improvement with decreased cryoglobulin levels</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While SVR to antiviral therapy is associated with improvement in cryoglobulinemic vasculitis, complete resolution is not always achieved. However, significant reductions in cryoglobulins and clinical improvement are expected.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. No improvement in vasculitis activity:</span></strong><span style=\"font-size:12.0pt\"> Achieving SVR often leads to significant improvement in symptoms and reduction of cryoglobulin levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Worsening of vasculitis:</span></strong><span style=\"font-size:12.0pt\"> While rare, there have been some cases where antiviral therapy can lead to a temporary worsening of vasculitis followed by improvement, and overall, antiviral therapy is expected to be beneficial.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Complete resolution of vasculitis:</span></strong><span style=\"font-size:12.0pt\"> While SVR often leads to significant improvement in vasculitis, complete resolution may not always occur. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antiviral therapy is essential for managing hepatitis C-associated cryoglobulinemic vasculitis. While SVR is associated with improved outcomes, patients may still require additional immunosuppressive therapy or other interventions to achieve complete remission of vasculitis.</span></span></span></p>",
      "correct_choice_id": 78820,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19715,
      "choices": [
        {
          "id": 78821,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-nuclear antibody (ANA) </span></span></span></p>"
        },
        {
          "id": 78822,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-double stranded DNA (anti-dsDNA) antibody </span></span></span></p>"
        },
        {
          "id": 78823,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-C1q antibody </span></span></span></p>"
        },
        {
          "id": 78824,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antineutrophil cytoplasmic antibody (ANCA)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 34-year-old woman presents with recurrent, long-lasting wheals on her trunk and limbs, accompanied by joint pain and abdominal discomfort. The lesions often leave a bruise-like mark. Laboratory tests reveal normal C3 and C4 complement levels. Which of the following autoantibodies is most likely to be elevated in this patient?</span></span></p>",
      "unique_key": "Q7367160",
      "question_audio": null,
      "question_video": null,
      "map_id": 19522,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Anti-C1q antibody</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and laboratory findings strongly suggest <strong>hypocomplementemic urticarial vasculitis</strong> (HUV), a variant of urticarial vasculitis characterized by low levels of complement components. While C3 and C4 levels may be normal, anti-C1q antibodies are often elevated in HUV. These antibodies are directed against the first component of the complement cascade and can activate the complement system, leading to the inflammatory response seen in urticarial vasculitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Anti-nuclear antibody (ANA):&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While ANA can be positive in some cases of HUV,&nbsp;it is not specific and can be found in other autoimmune diseases.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Anti-</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>double stranded DNA (dsDNA) antibody:&nbsp;</strong>This antibody is more specific for systemic lupus erythematosus (SLE).</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Antineutrophil cytoplasmic antibody (ANCA):&nbsp;</strong>ANCA is associated with other vasculitides,&nbsp;like granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA),&nbsp;not urticarial vasculitis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypocomplementemic Urticarial Vasculitis (HUV):</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Characterized by urticarial lesions lasting &gt;24 hours, leaving bruise-like marks, and systemic symptoms like joint pain and abdominal discomfort.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laboratory findings may show low complement levels, but normal C3 and C4 levels can occur.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-C1q antibodies are highly associated with HUV and considered a diagnostic marker.</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 78823,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19716,
      "choices": [
        {
          "id": 78825,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pathergy test</span></span></span></p>"
        },
        {
          "id": 78826,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-nuclear antibody (ANA) test</span></span></span></p>"
        },
        {
          "id": 78827,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rheumatoid factor (RF) test</span></span></span></p>"
        },
        {
          "id": 78828,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-neutrophil cytoplasmic antibody (ANCA) test</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old male presents with recurrent painful oral and genital ulcers. He also has a history of erythema nodosum. Which of the following tests is most likely to be positive and aid in the diagnosis of Beh&ccedil;et syndrome?</span></span></p>",
      "unique_key": "Q3125071",
      "question_audio": null,
      "question_video": null,
      "map_id": 19523,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Pathergy test</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The pathergy test is a nonspecific but highly sensitive test for Beh&ccedil;et disease. It involves a superficial needle prick, and a positive result is the development of a papule or pustule within 24-48 hours.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anti-nuclear antibody (ANA)</span></strong><span style=\"font-size:12.0pt\">, <strong>Option C. Rheumatoid factor (RF)</strong>, and <strong>Option D. Anti-neutrophil cytoplasmic antibody (ANCA)</strong> tests are not specific for Beh&ccedil;et&#39;s and are more commonly associated with other autoimmune diseases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the utility of the pathergy test is essential in the diagnosis of Beh&ccedil;et disease. While it is not pathognomonic, a positive pathergy test, along with the characteristic clinical manifestations, can strongly support the diagnosis.</span></span></span></p>",
      "correct_choice_id": 78825,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19717,
      "choices": [
        {
          "id": 78829,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HLA-B51 testing is the gold standard for diagnosing Beh&ccedil;et disease. </span></span></span></p>"
        },
        {
          "id": 78830,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A positive HLA-B51 test confirms the diagnosis of Beh&ccedil;et disease. </span></span></span></p>"
        },
        {
          "id": 78831,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A negative HLA-B51 test rules out the diagnosis of Beh&ccedil;et disease. </span></span></span></p>"
        },
        {
          "id": 78832,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HLA-B51 testing can be helpful, but it&#39;s not definitive for diagnosis due to its prevalence in the general population.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old man of Turkish descent presents with recurrent oral ulcers, genital ulcers, and uveitis. You suspect Beh&ccedil;et disease. Which of the following statements regarding HLA-B*51 testing in this patient is MOST accurate?</span></span></p>",
      "unique_key": "Q9195256",
      "question_audio": null,
      "question_video": null,
      "map_id": 19524,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) HLA-B*51 testing can be helpful, but it&#39;s not definitive for diagnosis due to its prevalence in the general population.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">HLA-B*51 and Beh&ccedil;et&#39;s Disease:</span></strong><span style=\"font-size:12.0pt\"> While HLA-B*51 is more common in Beh&ccedil;et&#39;s disease patients (especially certain ethnicities), it&#39;s also found in healthy people. So, a positive test is suggestive but not confirmatory. Up to 50&ndash;60% of patients, depending on where they are from, can be positive for HLA B*51; however, it is not used as a diagnostic test because it is also found in up to 20% of the normal population. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A.</span></strong> <strong><span style=\"font-size:12.0pt\">HLA-B51 testing is the gold standard for diagnosing Beh&ccedil;et disease&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;<strong>B. A positive HLA-B51 test confirms the diagnosis of Beh&ccedil;et disease:</strong>&nbsp;HLA-B*51 testing is not the gold standard for diagnosis and does not confirm the diagnosis on its own.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. A negative HLA-B51 test rules out the diagnosis of Beh&ccedil;et disease:</span></strong><span style=\"font-size:12.0pt\">&nbsp;A negative HLA-B51 test does not exclude the diagnosis of Beh&ccedil;et disease, as some patients with the disease are HLA-B51 negative.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HLA-B*51 testing should be interpreted with caution and in the context of the overall clinical picture. A positive test can increase suspicion for Beh&ccedil;et disease, but it does not confirm or rule out the diagnosis.</span></span></span></p>",
      "correct_choice_id": 78832,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19718,
      "choices": [
        {
          "id": 78833,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colchicine </span></span></span></p>"
        },
        {
          "id": 78834,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Azathioprine </span></span></span></p>"
        },
        {
          "id": 78835,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Apremilast </span></span></span></p>"
        },
        {
          "id": 78836,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cyclophosphamide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old woman with Beh&ccedil;et syndrome presents with recurrent, painful oral ulcers that have not responded to topical corticosteroids. She has no significant comorbidities. Which of the following medications is FDA-approved for the treatment of oral ulcers in Beh&ccedil;et syndrome and would be the most appropriate next step in management?</span></span></p>",
      "unique_key": "Q2729765",
      "question_audio": null,
      "question_video": null,
      "map_id": 19525,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Apremilast</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Apremilast:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This oral phosphodiesterase 4 inhibitor has been specifically approved for the treatment of oral ulcers in Beh&ccedil;et syndrome.&nbsp;It has shown efficacy in reducing the number and pain of oral ulcers in clinical trials.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Colchicine:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Primarily used for acute gout flares and sometimes for erythema nodosum in Beh&ccedil;et&#39;s,&nbsp;but not specifically approved for oral ulcers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Azathioprine:</span></strong><span style=\"font-size:12.0pt\">&nbsp;An immunosuppressant used for various autoimmune diseases,&nbsp;but not the first-line treatment for oral ulcers in Beh&ccedil;et&#39;s.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cyclophosphamide:</span></strong><span style=\"font-size:12.0pt\">&nbsp;A potent immunosuppressant used for severe manifestations of Beh&ccedil;et&#39;s (e.g.,&nbsp;ocular or neurological involvement),&nbsp;not typically the first choice for isolated oral ulcers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Apremilast is a relatively new treatment option for managing oral ulcers in Beh&ccedil;et syndrome. It offers a targeted approach with a favorable safety profile compared to more traditional immunosuppressive therapies.</span></span></span></p>",
      "correct_choice_id": 78835,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}